Fast Facts | For Your Patients | HPV | Continuing Education
HPV Survivor Stories
Anti-vaccination groups don’t fight with facts, they fight with emotion. They have multiple stories of their aunt/cousin/friend who has been adversely affected by a vaccine. We cannot fight these emotions with facts and figures and statistics; only with other emotional stories.
Links to Survivor Stories
Cervivor.org
Check out the CDC’s Same Day Same Way App!
Communication between providers and parents is key to improving HPV vaccination. HPV Vaccine: Same Way, Same Day™External is a brief, interactive role-play simulation designed to enhance healthcare providers’ ability to introduce the HPV vaccine and address HPV vaccine hesitant parents’ concerns. In this app, you will practice techniques to introduce and discuss the vaccine with parents and patients, including those who may be hesitant to immunize. It is ideal for immunization education and provider training.
Check it out in the Google Play and/or the Apple iTunes stores!
Want more CDC training? Click here!
2017 NIS-Teen MMWR – Vaccination Coverage Among Adolescents
The number of adolescents who are up to date on HPV vaccination – meaning they started and completed the HPV vaccine series – increased five percentage points from 2016 to 2017.
In 2017, nearly 66 percent of adolescents aged 13-17 years received the first dose to start the vaccine series, and nearly 49 percent of adolescents received all the recommended doses to complete the series. While HPV vaccination rates are increasing, there is room for improvement as many adolescents have not received all the recommended doses of the HPV and meningococcal conjugate vaccines. One of the new reports show that 51 percent of adolescents have not completed the HPV vaccine series, and 56 percent of adolescents have not received both doses of meningococcal conjugate vaccine.
Also, fewer adolescents in rural areas, compared with youth in urban areas, are getting the HPV and meningococcal conjugate vaccines. The number of adolescents who received the first dose of the HPV vaccine was 11 percentage points lower in rural areas compared to urban areas. The number of adolescents receiving the first dose of the meningococcal conjugate vaccine was 7 percentage points lower in rural areas compared to urban areas.
Read more
Fast Facts
- HPV vaccine prevents infection with HPV types associated with many cancers (cervical, vaginal & vulvar, anal, throat, penile) and genital warts. (2018 WHO Safety Update)
- Approved for ages 9-26, males & females.
- Should be given as a 2 dose series, with the doses separated by 6-12 months.
- If series is started at age 15 or later, give a 3 dose series (2nd dose 1-2 months after 1st, 3rd 6 months after 1st)
Percent of Adolescence Who are Up to Date on HPV Vaccination
Up-to-date HPV vaccination includes those with ≥ 3 doses and those with 2 doses when the first HPV vaccine was initiated at age < 15 years.
(Goal for 2030: 80%)
| Year | Nationally | Delaware |
|---|---|---|
| 2017 | 48.6 | 58.1 |
| 2018 | 51.1 | 58.4 |
| 2019 | 54.2 | 59.2 |
| 2020 | 58.6 | 63.2 |
| 2021 | 61.7 | 68.9 |
For Your Patients:
CDC: HPV Vaccine for Preteens and Teens: English | Spanish
HPV Fact Sheet: English | Spanish
HPV Gardasil-9 Vaccine Information Statement (12/02/2016): English | Spanish
Steps for Increasing HPV Vaccination in Practice: English | CDC Recommendations | Top 10 Tips
How to Answer Parents’ Questions: CDC
Six Reasons Fact Sheet: CDC
Infographic: here
National HPV Round Table: Resource Library
HPV VACs Newsletter: September-October 2017 Partner Newsletter
HPV VACs (3/09/2016): Just the Facts
YouTube Video: How the HPV Vaccine Works | Dr. Savoy Videos | Iceberg Infographic | HPV Roundtable TV
return to top
Human Papillomavirus (HPV)
From the CDC’s Pinkbook:
Anogenital HPV infection is believed to be the most common sexually transmitted infection in the United States. An estimated 79 million persons are infected, and an estimated 14 million new HPV infections occur annually with half of these in persons 15-24 years.
Infection with low-risk, or nononcogenic types of HPV, such as types 6 and 11, can cause benign or low-grade cervical cell abnormalities, genital warts and laryngeal papillomas.
High-risk HPV types are detected in 99% of cervical cancers. Type 16 is the cause of approximately 50% of cervical cancers worldwide, and types 16 and 18 together account for about 70% of cervical cancers. Infection with a high-risk HPV type is considered necessary for the development of cervical cancer, but by itself it is not sufficient to cause cancer because the vast majority of women with HPV infection do not develop cancer.
In addition to cervical cancer, HPV infection is also associated with anogenital cancers less common than cervical cancer, such as cancer of the vulva, vagina, penis and anus. The association of genital types of HPV with non-genital cancers is less well established, but studies support a role for these HPV types in some oropharyngeal cancers.
return to top
Continuing Education:
HPV Vaccination Strategies for Cancer Prevention – October 2017
HPV VACs Partner Newsletter – April 2017
HPV Vaccination Report: Delaware, March 2017
MMWR: Use of a 2-Dose Schedule for HPV Vaccination – Updated Recommendations of the ACIP, December 2016
Oral HPV Infection in England and Associated Risk Factors, BMJ, 2018
You Call The Shots, Module 8: HPV, updated in 2020
You are the key to HPV Cancer Prevention, updated April 2016
Talking to Parents about HPV Vaccine